Belgium's UCB has acquired the pharmaceuticals division of Japan's FUJIREBIO (annual sales of JPY 6 billion) for around JPY 5 billion. The activities of the Japanese group, namely the production and marketing of prescription medications in several fields, will be integrated into those of UCB JAPAN.